The sudden decision for Medicare to temporarily cover obesity drugs like Wegovy and Zepbound has put a spotlight on pharmaceutical companies working in obesity and metabolic disorders. With millions of eligible seniors now facing a defined $50 monthly copay and a clear end date for coverage in 2027, the stakes are high for both investors and patients. This article looks at how that catalyst connects to three stocks exposed to the news, all drawn from a focused screener of larger healthcare companies in this space, and explains why some investors may see them as opportunities while others may prefer to stay cautious.

Structure Therapeutics (GPCR)

Overview: Structure Therapeutics is a clinical stage biopharma company based in South San Francisco that focuses on oral small molecule drugs for chronic conditions, with its lead GLP-1 receptor agonist GSBR-1290 in phase 2 trials targeting obesity, overweight, and related metabolic issues. It is also building a broader pipeline in obesity, fibrosis, and cardiometabolic disease through amylin, APJ, lysophosphatidic acid, GIPR, and GCGR programs.

Market Cap: US$3.68b

Structure Therapeutics provides targeted exposure to one of the most closely watched themes in healthcare: oral GLP-1s for obesity. It is at a stage where clinical data and policy shifts, such as temporary Medicare coverage, could be more important than current revenue, which is still negligible and associated with a loss of US$75.97 million in Q1 2026. The pipeline is focused, with several oral metabolic candidates moving through trials. The company is forecast to remain unprofitable and has relied on external funding and dilution, which adds financing and valuation risk. Governance and management depth appear solid for a company of this size. The 62% forecast revenue growth rate illustrates the scale of potential impact if its oral GLP-1 approach gains wider adoption.

Structure Therapeutics is pursuing oral GLP-1s while still reporting a quarterly loss of US$75.97 million and relying on fresh capital, so before the story develops further, review the 1 key reward and 3 important warning signs (1 is major!)

Altimmune (ALT)

Overview: Altimmune is a late stage biopharmaceutical company developing pemvidutide, a dual GLP-1 and glucagon agonist designed to treat serious metabolic and liver diseases such as metabolic dysfunction associated steatohepatitis, alcohol use disorder and alcohol associated liver disease.

Market Cap: US$548.4m

Altimmune sits at the crossroads of two notable areas: GLP-1 based obesity treatments and a growing focus on metabolic liver disease. It remains a clinical stage company with minimal current revenue and ongoing losses. Pemvidutide is already in Phase 3 and management is discussing multiple indications. This could turn it into a multi use franchise if trials meet expectations and regulators remain comfortable with noninvasive testing. At the same time, Altimmune relies heavily on external funding, has recently raised fresh equity and shareholders have experienced substantial dilution, so execution missteps or trial setbacks could be painful. For investors interested in obesity and metabolic disorder drugs, a key consideration is whether Altimmune's risk and reward profile stands out against other GLP-1 developers in this Medicare driven environment.

Altimmune’s Phase 3 pemvidutide story is gaining attention, but the real question is how its risk and opportunity compare with those of larger GLP-1 players. For more detail, review the 1 key reward and 4 important warning signs (3 are major!).

Crinetics Pharmaceuticals (CRNX)

Overview: Crinetics Pharmaceuticals is a clinical stage company that develops oral drugs for rare endocrine diseases and hormone driven tumors, led by Paltusotine for acromegaly and carcinoid syndrome, and supported by a pipeline targeting conditions such as congenital adrenal hyperplasia, Cushing’s disease and thyroid and parathyroid disorders, plus early oral GLP-1 and GIP programs for obesity.

Operations: Crinetics Pharmaceuticals currently generates US$18.07m in revenue from pharmaceuticals, all from the United States.

Market Cap: US$3.89b

Crinetics Pharmaceuticals stands out in this obesity and metabolic disorders theme because it already has Palsonify for acromegaly progressing alongside a deep pipeline across adrenal, pituitary and tumor indications. It is also working on early oral GLP-1 and GIP candidates that could intersect with the broader obesity drug story and any extended reimbursement trends from moves such as Medicare’s GLP-1 coverage. Analysts have highlighted the potential for significant revenue expansion, but the company is still reporting sizeable losses and relies on external funding, so execution on launches and late stage trials is critical. For investors, the mix of rare disease pricing dynamics, expanding payer coverage for endocrine therapies and the possibility of further upside comes with clear risks related to ongoing unprofitability, funding needs and whether prescriptions for its flagship products can support the current valuation over time.

Crinetics Pharmaceuticals is advancing its work on rare endocrine diseases and early obesity programs, but the real story could be how its risks and upside compare with peers. To see what might be hiding in plain sight, review the 2 key rewards and 1 important warning sign

The three stocks in this article are just a starting point, and the full screener of obesity and metabolic disorder companies surfaced 6 more that also have detailed stories around GLP-1 exposure and metabolic pipelines, which you can review in the Healthcare - Pharmaceutical Companies specializing in Obesity and Metabolic Disorders screener. Using Simply Wall St, you can quickly identify and analyze the specific catalysts, clinical milestones and balance sheet traits discussed here so you can focus on the ideas you consider highest conviction for your own watchlist.

Take Control of Your Investment Journey

If Crinetics Pharmaceuticals or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About Seeking Fresh Alternatives?

Fresh ideas move first, and the stocks with real breakout momentum often get caught by screens before the crowd notices. Scan what is still under the radar for now and act now.

• Target steady income streams by reviewing 9 dividend fortresses that focus on companies already offering higher yields while they are still flying under most investors' radar.
• Spot early tech momentum and assess 52 AI infrastructure stocks that could benefit if demand for AI bandwidth and computing capacity keeps building before prices start dropping.
• Pinpoint resilient balance sheets using the curated list of solid balance sheet and fundamentals (48 results) so you can focus on businesses with strength while it still matters, before sentiment swings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.